Compare American Well Corp (AMWL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Twist Bioscience Corp — how do they compare? American Well Corp trades at $10.86 (market cap $165.58M), while Twist Bioscience Corp trades at $92.3 (market cap $5.64B). The key difference: Twist Bioscience Corp is far larger — about 34.1× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| AMWL | TWST | |
|---|---|---|
Market Cap | $165.58M | $5.64B |
Sector | Health | Health |
52-Week High | $9.91 | $102.88 |
52-Week Low | $3.78 | $24.16 |
Enterprise Value | -$9.66M | $5.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $9.91, up 8.66% today, with bullish technical signals and positive momentum. The company shows improving financial trends with declining losses and strong gross margins of 52.9%, though it remains unprofitable with a -37.02% net margin. Recent news highlights Amazon's appointment of Amwell's co-founder to lead its healthcare unit, signaling industry validation.
While AMWL shows operational improvement and attractive valuation multiples (P/S 0.68, P/B 0.73), the stock faces headwinds from persistent losses and negative cash flow. Analyst consensus is cautious with a $7.25 price target below current levels, suggesting limited near-term upside despite recent positive momentum.
Twist Bioscience (TWST) trades at $90.64, down 3.24% today, with a bullish technical signal from moving averages and ADX indicators. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a net income margin of -19.85%. Recent developments include AI-driven drug discovery collaborations and expansion of clonal genes offerings, positioning TWST in the growing synthetic biology market.
While analyst consensus is strongly bullish (77% buy ratings) with a $87.88 price target, investors face significant risks from persistent cash burn and competitive pressures. The stock's valuation appears stretched at 13.46x sales despite negative earnings, requiring careful monitoring of path to profitability and execution on AI partnerships for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
